Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Three patients with myelofibrosis received allogeneic stem cell transplantation after a dose-reduced conditioning regimen of busulphan (8 mg/kg), fludarabine (180 mg/m2) and antithymocyte globulin (4 x 10 mg/kg). The median age at transplantation was 51 years (range 44-58). All patients engrafted with a leucocyte count > 1.0 x 10(9)/l after a median of 18 d (range 16-20). Grade II acute skin graft-versus-host disease (GvHD) occurred in one patient. One limited and one extensive chronic GvHD was observed. All patients achieved complete haematological remission. In one patient the fibrosis resolved completely 180 d post transplant. All patients are alive 126, 466 and 764 d after transplantation.
Hessling
Jörg
J
Bone Marrow Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Kröger
Nicolaus
N
Werner
Mathias
M
Zabelina
Tatjana
T
Hansen
Arne
A
Kordes
Uwe
U
Ayuk
Francis Ayuketang
FA
Renges
Helmut
H
Panse
Jörg
J
Erttmann
Rudolf
R
Zander
Axel Rolf
AR
D000328:Adult; D002066:Busulfan / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000150:complications / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine